(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.01%) $0.926
(-0.07%) $10.83
(-0.13%) $0.791
(-0.21%) $92.38
Live Chart Being Loaded With Signals
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany...
Stats | |
---|---|
Today's Volume | 10.21M |
Average Volume | 4.35M |
Market Cap | 0.00 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.187 |
ATR14 | €0 (0.00%) |
NOXXON Pharma NV Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
NOXXON Pharma NV Financials
Annual | 2021 |
Revenue: | €0.00 |
Gross Profit: | €0.00 (0.00 %) |
EPS: | €-45.99 |
Q2 | 2019 |
Revenue: | €0.00 |
Gross Profit: | €-257 250 (0.00 %) |
EPS: | €-1.929 |
Q1 | 2019 |
Revenue: | €0.00 |
Gross Profit: | €-257 250 (0.00 %) |
EPS: | €-1.929 |
Q1 | 2019 |
Revenue: | €0.00 |
Gross Profit: | €-257 250 (0.00 %) |
EPS: | €-1.929 |
Financial Reports:
No articles found.
NOXXON Pharma NV
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators